REMEGEN (09995) announced its financial results for the first three quarters of 2025, with revenue reaching approximately RMB 1.72 billion, a year-on-year increase of 42.27%. The net loss attributable to shareholders stood at around RMB 551 million, narrowing by 48.6% compared to the same period last year. Basic loss per share was RMB 1.01.

The company attributed the reduced net loss primarily to a significant increase in product sales revenue, optimization of its R&D pipeline leading to lower research expenditures, and a licensing agreement with U.S.-based Vor Bio. Under the agreement, REMEGEN granted Vor Bio exclusive rights to develop and commercialize its self-developed drug, Telitacicept, outside Greater China. This resulted in reduced overseas clinical trial costs for Telitacicept, contributing to the substantial decrease in losses for the year.